Mycobacteriophage Compositions and Related Methods, Oregon State University
Summary
USPTO published patent application US20260108571A1 for Oregon State University on April 23, 2026, covering isolated bacteriophages with lytic activity against mycobacterial species, including the specific phage Pill582 and variants thereof. The application (filed 2025-10-20, Application No. 19363116) discloses phage cocktails, pharmaceutical compositions, and methods for treating mycobacterial infections and associated disease conditions.
“Disclosed are isolated bacteriophages having lytic activity against a broad range of mycobacterial species, as well as phage cocktails comprising different mixtures of the isolated bacteriophages.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 215 changes logged to date.
What changed
USPTO published patent application US20260108571A1 disclosing isolated bacteriophages (Pill582 and variants) having lytic activity against broad mycobacterial species, with TLR2 signaling and NLRP3 inflammasome activation capabilities. The application covers phage cocktails, pharmaceutical compositions, and methods of treating mycobacterial infections. Patent applications are informational publications that do not create compliance obligations. They establish priority dates and make invention details publicly available for examination.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MYCOBACTERIOPHAGE COMPOSITIONS AND RELATED METHODS
Application US20260108571A1 Kind: A1 Apr 23, 2026
Assignee
Oregon State University
Inventors
Lia Danelishvili
Abstract
Disclosed are isolated bacteriophages having lytic activity against a broad range of mycobacterial species, as well as phage cocktails comprising different mixtures of the isolated bacteriophages. The disclosed bacteriophages include Pill582, and variants thereof, having the ability to stimulate TLR2 signaling and limit intracellular bacterial survival within macrophages through the signalosome involving NLRP3 inflammasome activation leading to the caspase 1 activation and the production of pro-inflammatory cytokine IL-1β. Also disclosed are compositions comprising the isolated bacteriophages or phage cocktails, including pharmaceutical compositions and compositions further comprising one or more non-phage therapeutic agents. The disclosed bacteriophage and phage cocktail compositions are useful in methods for treating mycobacterial infections and associated disease conditions.
CPC Classifications
A61K 35/76 A61P 31/06 C12N 7/00 C12N 2795/10021 C12N 2795/10032
Filing Date
2025-10-20
Application No.
19363116
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.